Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25913868 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNA4MEN1CYP2D6CYP2C19 | |
| SCHEMBL174625 | 0.95 | CREBBP (0.45) | CHRNB2CHRNA4MEN1CYP2D6CYP2C19 | |
| SCHEMBL20187374 | 0.95 | CREBBP (0.45) | CHRNB2CHRNA4MEN1CYP2D6CYP2C19 | |
| SCHEMBL9592064 | 0.78 | HCAR2 (0.35) | CREBBP | |
| SCHEMBL19723894 | 0.76 | HCAR2 (0.42) | CYP2C19SMN1; SMN2CHRM1 | |
| SCHEMBL24363809 | 0.75 | HCAR2 (0.35) | — | |
| SCHEMBL22473331 | 0.74 | CHRNA7 (0.32) | CHRNA7 | |
| SCHEMBL19723890 | 0.74 | HCAR2 (0.41) | CYP2D6CYP2C19CYP1A2CYP2C9CHRM1 | |
| SCHEMBL22473550 | 0.74 | MPO (0.35) | — | |
| SCHEMBL22473301 | 0.74 | MPO (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11999727-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| CN-108290881-B | Therapeutic compounds and methods of use thereof | 健泰科生物技术公司 | 2021-12-07 | — | — | CN | disclosed |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20180291014-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| EP-3356360-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999727-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNA4 2950/4885MEN1 142/4885 |
| US-20180291014-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | CHRNB2 1972/4885CHRNA4 2525/4885MEN1 463/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNA4 2950/4885MEN1 142/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNA4 2950/4885MEN1 142/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNA4 2950/4885MEN1 142/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNA4 2950/4885MEN1 142/4885 |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | AVPR1B, C3AR1, RHEB | CHRNB2 1972/4885CHRNA4 2525/4885MEN1 463/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNA4 2950/4885MEN1 142/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNA4 2950/4885MEN1 142/4885 |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | CHRNB2 1972/4885CHRNA4 2525/4885MEN1 463/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | CHRNB2 903/4885CHRNA4 1365/4885MEN1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.